Literature DB >> 1619397

Inactivated Lassa virus elicits a non protective immune response in rhesus monkeys.

J B McCormick1, S W Mitchell, M P Kiley, S Ruo, S P Fisher-Hoch.   

Abstract

We attempted to protect three rhesus monkeys from Lassa fever by vaccination with a preparation of purified whole Lassa virus which had been inactivated by gamma irradiation. The vaccinated monkeys developed antibodies against the three major viral proteins of Lassa virus demonstrated by radioimmunoprecipitation. When the three vaccinated monkeys and two unvaccinated control monkeys were challenged all five became severely ill and died. Prior to death a secondary, high-titer antibody response to Lassa virus was observed in the three vaccinated monkeys, whereas the two unvaccinated monkeys developed a primary, low-titer antibody response. Though titers of Lassa virus in serum reached peak levels earlier following challenge in the non vaccinated, at the time of death serum and organ virus titers did not differ significantly. Changes in platelet aggregation, leukocyte counts, and liver enzymes, abnormalities of which have been associated with severity of Lassa fever, were found to be comparable in the two groups. The humoral antibody response measured in these animals following vaccination, although of the same magnitude as found in humans recovered from Lassa fever, was insufficient to protect the animals from this fatal disease. Evidence is now accumulating that the cell-mediated immune response must be activated in order to protect against challenge with arenaviruses.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1619397     DOI: 10.1002/jmv.1890370102

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  35 in total

1.  Genomic profiling of host responses to Lassa virus: therapeutic potential from primate to man.

Authors:  Juan C Zapata; Maria S Salvato
Journal:  Future Virol       Date:  2015-03-13       Impact factor: 1.831

2.  Protection From Lethal Lassa Disease Can Be Achieved Both Before and After Virus Exposure by Administration of Single-Cycle Replicating Lassa Virus Replicon Particles.

Authors:  Markus H Kainulainen; Jessica R Spengler; Stephen R Welch; JoAnn D Coleman-McCray; Jessica R Harmon; Florine E M Scholte; Cynthia S Goldsmith; Stuart T Nichol; César G Albariño; Christina F Spiropoulou
Journal:  J Infect Dis       Date:  2019-09-13       Impact factor: 5.226

3.  Adjuvant formulated virus-like particles expressing native-like forms of the Lassa virus envelope surface glycoprotein are immunogenic and induce antibodies with broadly neutralizing activity.

Authors:  Helena Müller; Sarah Katharina Fehling; Jens Dorna; Richard A Urbanowicz; Lisa Oestereich; Yvonne Krebs; Larissa Kolesnikova; Martin Schauflinger; Verena Krähling; N'Faly Magassouba; Elisabeth Fichet-Calvet; Jonathan K Ball; Andreas Kaufmann; Stefan Bauer; Stephan Becker; Veronika von Messling; Thomas Strecker
Journal:  NPJ Vaccines       Date:  2020-08-04       Impact factor: 7.344

4.  Pre-clinical development of a vaccine against Lassa fever.

Authors:  L Banadyga; D R Stein; X Qiu; D Safronetz
Journal:  Can Commun Dis Rep       Date:  2018-06-07

5.  A Case of Human Lassa Virus Infection With Robust Acute T-Cell Activation and Long-Term Virus-Specific T-Cell Responses.

Authors:  Anita K McElroy; Rama S Akondy; Jessica R Harmon; Ali H Ellebedy; Deborah Cannon; John D Klena; John Sidney; Alessandro Sette; Aneesh K Mehta; Colleen S Kraft; Marshall G Lyon; Jay B Varkey; Bruce S Ribner; Stuart T Nichol; Christina F Spiropoulou
Journal:  J Infect Dis       Date:  2017-06-15       Impact factor: 5.226

Review 6.  The search for animal models for Lassa fever vaccine development.

Authors:  Igor S Lukashevich
Journal:  Expert Rev Vaccines       Date:  2013-01       Impact factor: 5.217

7.  The nucleoprotein of Pichinde virus expressed by a vaccinia-Pichinde virus recombinant partially protects hamsters from lethal virus challenge.

Authors:  D Y Ozols; W E Rawls; K L Rosenthal; D G Harnish
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

8.  A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity.

Authors:  Ricardo Carrion; Jean L Patterson; Curtis Johnson; Monica Gonzales; Carmen R Moreira; Anysha Ticer; Kathleen Brasky; Gene B Hubbard; Dmitry Moshkoff; Juan Zapata; Maria S Salvato; Igor S Lukashevich
Journal:  Vaccine       Date:  2007-02-27       Impact factor: 3.641

9.  Mucosal arenavirus infection of primates can protect them from lethal hemorrhagic fever.

Authors:  Juan D Rodas; Igor S Lukashevich; Juan C Zapata; Cristiana Cairo; Ilia Tikhonov; Mahmoud Djavani; C David Pauza; Maria S Salvato
Journal:  J Med Virol       Date:  2004-03       Impact factor: 2.327

10.  Structural basis for antibody-mediated neutralization of Lassa virus.

Authors:  Kathryn M Hastie; Michelle A Zandonatti; Lara M Kleinfelter; Megan L Heinrich; Megan M Rowland; Kartik Chandran; Luis M Branco; James E Robinson; Robert F Garry; Erica Ollmann Saphire
Journal:  Science       Date:  2017-06-02       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.